Print Page  Close Window    

8-K
MICROBOT MEDICAL INC. filed this Form 8-K on 12/12/2014
Entire Document
 
StemCells, Inc. (Form: 8-K)  

 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   December 12, 2014

StemCells, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-19871 94-3078125
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
7707 Gateway Blvd, Suite 140, Newark, California   94560
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   510.456.4000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 1.02 Termination of a Material Definitive Agreement.

On December 12, 2014, StemCells, Inc. (the "Company") received a CIRM Notice of Loan Award Termination to terminate the Company’s loan award, DR2A-05416 ("Loan Award").

In September 2012, CIRM awarded the Company up to approximately $19 million to fund the Company’s research of restoration of memory in Alzheimer’s disease using neural stem cell therapy. The decision to terminate the Loan Award was due to the occurrence of a No Go Milestone in accordance with Section 8.1(f) of the loan agreement. The final amount of the Loan Award will be determined upon submission of the final financial report and the loan balance will be forgiven.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    StemCells, Inc.
          
December 12, 2014   By:   /s/ Kenneth Stratton
       
        Name: Kenneth Stratton
        Title: General Counsel